Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1981 1
1982 1
1984 3
1985 1
1986 2
1987 3
1988 3
1989 1
1990 5
1991 6
1992 2
1993 7
1994 14
1995 8
1996 10
1997 7
1998 18
1999 14
2000 24
2001 23
2002 28
2003 35
2004 55
2005 81
2006 104
2007 129
2008 139
2009 154
2010 160
2011 179
2012 214
2013 286
2014 276
2015 360
2016 374
2017 376
2018 387
2019 507
2020 581
2021 759
2022 856
2023 775
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

6,232 results

Results by year

Filters applied: . Clear all
Page 1
Dual-comb optomechanical spectroscopy.
Ren X, Pan J, Yan M, Sheng J, Yang C, Zhang Q, Ma H, Wen Z, Huang K, Wu H, Zeng H. Ren X, et al. Among authors: yan m. Nat Commun. 2023 Aug 18;14(1):5037. doi: 10.1038/s41467-023-40771-3. Nat Commun. 2023. PMID: 37596269 Free PMC article.
Editorial: Advances in drug-induced diseases.
Liu Y, Wang JB, Zeng L, Gossell-Williams M, Moriel P, Yan M. Liu Y, et al. Among authors: yan m. Front Pharmacol. 2023 Apr 11;14:1193099. doi: 10.3389/fphar.2023.1193099. eCollection 2023. Front Pharmacol. 2023. PMID: 37113756 Free PMC article. No abstract available.
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Zhang P, Zhang Q, Tong Z, Sun T, Li W, Ouyang Q, Hu X, Cheng Y, Yan M, Pan Y, Teng Y, Yan X, Wang Y, Xie W, Zeng X, Wang X, Hu C, Geng C, Zhang H, Li W, Wu X, Zhong J, Xu J, Shi Y, Wei W, Bayaxi N, Zhu X, Xu B. Zhang P, et al. Among authors: yan m. Lancet Oncol. 2023 Jun;24(6):646-657. doi: 10.1016/S1470-2045(23)00172-9. Epub 2023 May 11. Lancet Oncol. 2023. PMID: 37182538 Clinical Trial.
Mid-infrared single-photon 3D imaging.
Fang J, Huang K, Wu E, Yan M, Zeng H. Fang J, et al. Among authors: yan m. Light Sci Appl. 2023 Jun 9;12(1):144. doi: 10.1038/s41377-023-01179-2. Light Sci Appl. 2023. PMID: 37296123 Free PMC article.
6,232 results